Anti-LRRK2/Dardarin, C-Terminus Antibody (N241A/34)
Primary Antibody
Human, Mouse, Rat
N241A/34
ICC, IHC, WB
Mouse
Purified
LRRK2 PARK8
>200 kDa
Adult rat brain immunohistochemistry (with antigen retrieval via sodium citrate pretreatment).
Product Specific References for Applications and Species
- ELISA: Human
- Immunocytochemistry: Drosophila | Human | Mouse | Rat
- Immunohistochemistry: Human | Mouse | Rat
- Immunoprecipitation: Human | Mouse
- PLA: Human | Mouse | Rat
- Western Blot: Drosophila | Human | Mouse | Non-Human Primate | Rat
- Additional Publications: Unspecified
| ELISA: Human | ||
| PMID | Dilution | Publication |
| 32652692 | not listed | Melachroinou, K., et al. 2020. Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method. Movement Disorders, 2095-2100. |
| 32523511 | 1 ug/ul | Mabrouk, O.S., et al. 2020. Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients. Frontiers in Neuroscience, . |
| 32007961 | 1:10 | Padmanabhan, S., et al. 2020. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts. NPJ Parkinson's Disease, 623-629. |
| 30858560 | not listed | Schaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329. |
| Immunocytochemistry: Drosophila | ||
| PMID | Dilution | Publication |
| 34250948 | not listed | Fellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820. |
| Immunocytochemistry: Human | ||
| PMID | Dilution | Publication |
| 36905628 | 1:3 (supe) | Filippini, F., et al. 2023. Secretion of VGF Relies on the Interplay Between LRRK2 and Post-Golgi v-SNAREs. Cell Reports, 112221. |
| 35599495 | 1:1000 | Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447. |
| 34604446 | 1:1000 | Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140. |
| 34114604 | 1mg/ml | Calamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, . |
| 32359446 | not listed | Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955. |
| 29472595 | not listed | Antoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455. |
| 26651604 | not listed | Schwab, A.J., et al. 2015. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson''s Disease-Related LRRK2 G2019S Mutation.. Stem Cell Reports., 1039-1052. |
| Immunocytochemistry: Mouse | ||
| PMID | Dilution | Publication |
| 35599495 | 1:50 | Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447. |
| 31663853 | not listed | Berndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416. |
| 29054882 | 1:500 | Pan, P.Y., et al. 2017. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Journal of Neuroscience, 11366-11376. |
| 28710481 | 1:100 | Carrion, M.D.P., et al. 2017. The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Scientific Reports, 5377. |
| 26365310 | 1:50 | Choi, I., et al. 2015. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.. Nature Communication, 8255. |
| Immunocytochemistry: Rat | ||
| PMID | Dilution | Publication |
| 37384414 | 1:100 | Williamson, MG, et al. 2023. Mitochondrial Dysfunction and Mitophagy Defects in LRRK2-R1441C Parkinson's Disease Models. Human molecular genetics, 0. |
| 35577065 | 1:1000 | Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754. |
| 24927544 | not listed | Daher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294. |
| Immunohistochemistry: Human | ||
| PMID | Dilution | Publication |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| Immunohistochemistry: Mouse | ||
| PMID | Dilution | Publication |
| 33483550 | 1:600 | Lebovitz, C., et al. 2021. Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Scientific Reports, 2097. |
| 30927072 | 1:1000 | Bieri, G., et al. 2019. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathologica Communications, 961-980. |
| 27911006 | 1:100 - 1:400 | Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432. |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| 23560750 | 1:1000 | Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13. |
| Immunohistochemistry: Rat | ||
| PMID | Dilution | Publication |
| 35577065 | 1:500 | Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754. |
| 33636387 | 1:500 | De Miranda, B.R., et al. 2021. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Neurobiology of Disease, 105312. |
| 24927544 | not listed | Daher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294. |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| 23560750 | 1:1000 | Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13. |
| Immunoprecipitation: Human | ||
| PMID | Dilution | Publication |
| 32359446 | not listed | Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955. |
| 23560750 | 1:1000 | Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13. |
| Immunoprecipitation: Mouse | ||
| PMID | Dilution | Publication |
| 29212815 | not listed | Purlyte, E., et al. 2018. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO Journal, 1-18. |
| 24282027 | not listed | Stafa, K., et al. 2014. Functional interaction of Parkinson''s disease-associated LRRK2 with members of the dynamin GTPase superfamily.. Human Molecular Genetics, 2055-2077. |
| PLA: Human | ||
| PMID | Dilution | Publication |
| 34604446 | 1:500 | Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140. |
| PLA: Mouse | ||
| PMID | Dilution | Publication |
| 35599495 | 1:1000 | Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447. |
| PLA: Rat | ||
| PMID | Dilution | Publication |
| 34604446 | 1:500 | Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140. |
| Western Blot: Drosophila | ||
| PMID | Dilution | Publication |
| 34250948 | not listed | Fellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820. |
| 34030727 | 1:200 | Sarkar, S., et al. 2021. Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo. . Molecular Neurodegeneration, 44579. |
| 32321836 | 1:1000 | Petridi, S., et al. 2020. In vivo visual screen for dopaminergic Rab↔ LRRK2-G2019S interactions in Drosophila discriminates Rab10 from Rab3.. Genes, Genomes, Genetics, 1903-1914. |
| 29214211 | 1:1000 | Cording, A.C., et al. 2017. Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease. NPJ Parkinson's Disease, 34. |
| Western Blot: Human | ||
| PMID | Dilution | Publication |
| 37141099 | 1:1000 | Rinaldi, C., et al. 2023. Dissecting the Effects of GTPase and Kinase Domain Mutations on LRRK2 Endosomal Localization and Activity. Cell Reports, 112447. |
| 36007011 | 1:1000 | Liu, X., et al. 2022. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of American Chemical Society, . |
| 35347144 | 1:1000 | Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 Protein and Activity on Stimulated Cytokines in Human Monocytes and Macrophages. NPJ Parkinson's Disease, 34. |
| 35347144 | 1:1000 | Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinson's Disease, 34. |
| 35326469 | 1ug/ml | Marchand, A., et al. 2022. A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively. Cells, 1018. |
| 35016853 | not listed | Cogo, S., et al. 2022. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain research, 147781. |
| 34580980 | 1ug/ml | Waschbüsch, D., et al. 2021. Structural basis for the specificity of PPM1H phosphatase for Rab GTPases. EMBO Reports, e52675. |
| 34515301 | not listed | Tasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573. |
| 34315807 | not listed | Liu, Q., et al. 2021. Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration. Science Signaling, eabg3555. |
| 34145320 | 1:500 | Wang, X., et al. 2021. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Scientific Reports, 12900. |
| 34125248 | 1ug/ml | Fan, Y., et al. 2021. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathologica Communications, 475-494. |
| 34114604 | 1:1000 | Calamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, . |
| 34008015 | not listed | Cheung, M., et al. 2021. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 1750-1761. |
| 33938021 | not listed | Lai, D., et al. 2021. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.. Annals of Neurology, 76-88. |
| 33887226 | 1:1000 | Waschbüsch, D., et al. 2021. Dual arginine recognition of LRRK2 phosphorylated Rab GTPases. Biophysical Journal, 1846-1855. |
| 33836114 | not listed | Bright, J.M., et al. 2021. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. Movement Disorders, 1362-1371. |
| 33197196 | 1:10,000 | Garofalo, A.W., et al. 2021. Selective Inhibitors of G2019S-LRRK2 Kinase Activity. Journal of Medicinal Chemistry, 14821-14839. |
| 33049313 | not listed | Harney, J., et al. 2021. An in vitro alveolar epithelial cell model recapitulates LRRK2 inhibitor-induced increases in lamellar body size observed in preclinical models. Toxicology In Vitro, 105012. |
| 33057100 | 1:200 | Gonzalez-Hunt, C.P., et al. 2020. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. Scientific Reports, 17293. |
| 32800998 | 1:1000 | Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 105049. |
| 32643832 | not listed | Herbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494. |
| 32461697 | not listed | Whiffin, N., et al. 2020. The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 869-877. |
| 32359446 | not listed | Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955. |
| 32227113 | not listed | Vieweg, S., et al. 2020. PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.. Biochemical Journal, 1651-1668. |
| 32017888 | 1:1000 | Waschbüsch, D., et al. 2020. Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure, 406-417. |
| 30858560 | not listed | Schaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329. |
| 30597610 | 1:1000 | Atashrazm, F., et al. 2019. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disorders, 406-415. |
| 30460108 | not listed | Jang, J., et al. 2018. Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Animal Cells and Systems, 273-280. |
| 29472595 | not listed | Antoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455. |
| 29357897 | 1:1000 | Madero-Pérez, J., et al. 2018. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. . Molecular neurodegeneration, 44583. |
| 29177506 | not listed | Liu, Z., et al. 2018. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Human Molecular Genetics, 385-395. |
| 29166931 | not listed | Wang, S., et al. 2017. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathologica Communications, 86. |
| 28860483 | 1:2000 | Thirstrup, K., et al. 2017. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Scientific Reports, 10300. |
| 26251043 | not listed | Henry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028. |
| 25939886 | not listed | Zhao, J., et al. 2015. LRRK2 dephosphorylation increases its ubiquitination. Biochemical Journal, 107-120. |
| 25080504 | 1:1000 | Gómez-Suaga, P., et al. 2014. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.. Human Molecular Genetics, 6779-6796. |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| 24427314 | not listed | Dorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One, e85510. |
| 23560750 | 1:1000 | Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13. |
| 23065705 | 1:15,000 | Yao, C., et al. 2013. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.. Human Molecular Genetics, 328-344. |
| 22012985 | not listed | Gómez-Suaga, P., et al. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP.. Human Molecular Genetics, 511-525. |
| Western Blot: Mouse | ||
| PMID | Dilution | Publication |
| 37289222 | not listed | Cabezudo, D, et al. 2023. Mutant LRRK2 Exacerbates Immune Response and Neurodegeneration in a Chronic Model of Experimental Colitis. Acta Neuropathologica, 245-261. |
| 36040231 | 1:1000 | Malik, A.U., et al. 2022. PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain. Biochemical Journal, . |
| 35776681 | 1:1000 | Lara Ordóñez, A.J., et al. 2022. The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization. Biology Open, . |
| 35599495 | 1:1000 | Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447. |
| 35269482 | 1:400 | Ho, D.H., et al. 2022. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells, 861. |
| 35012605 | not listed | Xu, E., et al. 2022. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular neurodegeneration, 7. |
| 34759048 | not listed | Kim, J.W., et al. 2021. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. eNeuro, . |
| 34515301 | not listed | Tasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573. |
| 33459343 | 1:1000 | Malik, A.U., et al. 2021. Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. . Biochemical Journal, 553-578. |
| 33298972 | 1:1000 | Wang, S., et al. 2020. Exosome markers of LRRK2 kinase inhibition. NPJ Parkinson's Disease, 32. |
| 33135724 | not listed | Kalogeropulou, A.F., et al. 2020. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. Biochemical Journal, 4397-4423. |
| 32853409 | not listed | Liu, Z., et al. 2020. LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. EMBO Journal, e104862. |
| 32800998 | 1:1000 | Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutatio. Neurobiology of Disease, . |
| 32643832 | not listed | Herbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494. |
| 31881263 | 1:5 (supe) | Kofoed, R.H., et al. 2020. Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein. Neurobiology of Disease, 104720. |
| 31663853 | 1:1000 | Berndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416. |
| 30949397 | not listed | Ho, D.H., et al. 2019. G2019s LRRK2 promotes mitochondrial fission and increases TNFα-mediated neuroinflammation responses. Animal Cells and Systems, 106-111. |
| 30592011 | not listed | Ulusoy, A., et al. 2019. Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization. Molecular Neurobiology, 5273-5286. |
| 30048714 | 1:2000 | Kelly, K., et al. 2018. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition. Experimental Neurology, 1-13. |
| 30022868 | not listed | Ho, D.H., et al. 2018. LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation. Experimental Neurobiology, 171-180. |
| 29743203 | 1ug/ml | Mir, R., et al. 2018. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochemical Journal, 1861-1883. |
| 29088368 | not listed | Nguyen, A.P.T., et al. 2018. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Human Molecular Genetics, 120-134. |
| 29246723 | not listed | Schapansky, J., et al. 2017. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. Neurobiology of Disease, 26-35. |
| 27943591 | 1:500 | Qin, Q., et al. 2017. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission. CNS Neuroscience and Therapeutics, 162-173. |
| 27911006 | 1:1000 | Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432. |
| 26251043 | not listed | Henry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028. |
| 25228699 | not listed | Liu, Z., et al. 2014. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.. Journal of Biological Chemistry, 32937-32951. |
| 24682598 | not listed | Schapansky, J., et al. 2014. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.. Human Molecular Genetics, 4201-4214. |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| 24427314 | not listed | Dorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One., e85510. |
| Western Blot: Non-Human Primate | ||
| PMID | Dilution | Publication |
| 25653221 | not listed | Fuji, R.N., et al. 2015. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.. Science Translastional Medicine, . |
| Western Blot: Rat | ||
| PMID | Dilution | Publication |
| 35266954 | not listed | Stormo, A.E., et al. 2022. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Journal of Cell Biology, e202010065. |
| 34658337 | 1:1000 | Khan, S.S., et al. 2021. Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain. Elife, e67900. |
| 34306319 | not listed | Ho, D.H., et al. 2021. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells. Oxidative Medicine and Cell Longevity, 9969842. |
| 33600829 | not listed | Kelly, K., et al. 2021. Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. Brain Research, 147372. |
| 33594532 | 1:200 | Van der Perren, A., et al. 2021. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo. Neurotherapeutics, 949-961. |
| 32681050 | 1:2000 | Østergaard, F.G., et al. 2020. Classification of α-synuclein-induced changes in the AAV α-synuclein rat model of Parkinson's disease using electrophysiological measurements of visual processing. Scientific Reports, 11869. |
| 32631998 | not listed | Nguyen, A.P.T., et al. 2020. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. PNAS: USA, 17296-17307. |
| 31626293 | not listed | Shani, V., et al. 2019. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Human Molecular Genetics, 3982-3996. |
| 29307545 | 1:2000 | Andersen, M.A., et al. 2018. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology, 15-22. |
| 25904107 | 1:1000 | Boddu, R., et al. 2015. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.. Human Molecular Genetics, 4078-4093. |
| 25174649 | 1:1000 | Lee, J.W., et al. 2015. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.. Neurobiol Aging, 505-518. |
| 24633735 | not listed | West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480. |
| 23560750 | 1:1000 | Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13. |
| Additional Publications: Unspecified | ||
| PMID | Publication | |
| 34144124 | Drouyer, M., et al. 2021. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. . Neurobiology of Disease, 105426. | |
| 32250352 | Fan, Y., et al. 2020. Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation. Journal of Visulized Experiments, . | |
| 31527116 | Fernández, B., et al. 2019. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients. Biochemical Journal, 2797-2813. | |
| 31046837 | Lee, J.H., et al. 2019. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes. Acta Neuropathologica Communications, 68. | |
| 30670570 | Leandrou, E., et al. 2019. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes. Biochemical Journal, 559-579. | |
| 29519959 | Kalogeropulou, A.F., et al. 2018. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity. Biochemical Journal, 1271-1293. | |
| 29127256 | Lis, P., et al. 2018. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochemical Journal, 1-22. | |
| 29125462 | Steger, M., et al. 2017. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife, e31012. | |
| 29023112 | Williamson, D.S., et al. 2017. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of Medicinal Chemistry, 8945-8962. | |
| 28973664 | Howlett, E.H., et al. 2017. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. Human Molecular Genetics, 4340. | |
| 28321439 | Xiong, Y., et al. 2017. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro, . | |
| 28115417 | Kim, M.J., et al. 2017. The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics, 729-741. | |
| 27503089 | Perera, G., et al. 2016. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 31391. | |
| 27297049 | Fraser, K.B., et al. 2016. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 1543-1550. | |
| 26865512 | Fraser, K.B., et al. 2016. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology, 994-999. | |